BeyondSpring Inc's (NASDAQ:BYSI) lead candidate plinabulin is likely to receive approval around the Nov. 30 PDUFA date for chemotherapy-induced neutropenia (CIN), according to Baird. The BeyondSpring Analyst: Joel Beatty initiated coverage of BeyondSpring with an Outperform rating and a price target of $50.
Full Story >>
Vote
+38